Understanding Biomarker Method Validation: A Scientific Perspective on Calibration Strategies

February 5th, 2025, 2:30 PM EST- Editorial Note:

We have observed that the January 2025 FDA Biomarker Assay Validation guidance document referenced in this post is currently inaccessible through the provided URL (listed in the reference section at the bottom of this article). This development, while noteworthy, does not impact the scientific principles discussed here. The fundamental distinctions between drug concentration assays and biomarker measurements reflect underlying technical realities that exist independently of specific regulatory frameworks. Our focus remains on understanding and implementing scientifically sound approaches to biomarker validation. We will continue to explore these critical scientific considerations throughout our blog series, helping our community navigate both technical and regulatory landscapes effectively.

Introduction

The January 2025 FDA Biomarker Assay Validation guidance maintains consistency with their previous regulatory documents in suggesting that biomarker validation should start with approaches used for drug concentration assays. However, the scientific reality requires a more nuanced understanding of why biomarker validation demands different technical approaches.

Understanding Drug Concentration Assays

In traditional pharmacokinetic (PK) assays, the validation approach benefits from a fundamental advantage: the reference standard used for calibration is identical to the analyte being measured in study samples. This allows for straightforward validation where known concentrations of a true reference standard are spiked into matrix, with recoveries evaluated against nominal concentration. The identity between the calibrator and analyte means spike-recovery experiments directly demonstrate method performance.

The Scientific Challenge of Biomarker Assays

Biomarker measurement presents a fundamentally different scientific challenge. When measuring endogenous molecules, we must often use surrogate recombinant calibrator material to quantify an endogenous analyte that differs from our reference standard. This creates a critical scientific consideration: how do we ensure our measurements accurately reflect the endogenous molecule we aim to quantify?

Scientific Solutions for Biomarker Calibration

Our experience implementing biomarker assays in successful drug development programs has shown that scientifically sound calibration requires several interconnected approaches:

1. Calibration Strategy: We employ surrogate recombinant calibrator material to generate standard curves and define provisional analytical ranges, with the aim of providing relative quantitation for the endogenous analyte. Therefore, similarity between the calibrator and endogenous analyte dilution-response curves must be demonstrated.
2. Parallelism Requirements: Critical to method validation is demonstrating that our assay’s critical reagents recognize both the standard calibrator material and endogenous analyte similarly. Demonstration of parallelism indicates that the chosen standard calibrator is appropriate for relative quantification of the endogenous analyte.  Additionally, the demonstration of parallelism across multiple individuals establishes selectivity, ensuring reliable measurement of endogenous analyte across individuals.
3. Analytical Range Determination: Unlike drug assays where ranges are confirmed by spiked standards, biomarker LLOQ is estimated by evaluating the lowest concentration reliably measured in parallelism studies across multiple individual samples containing endogenous analyte. The ULOQ evolves through ongoing in-study validation as high-concentration endogenous analyte samples become available.

Understanding these distinctions explains why simply applying PK validation approaches to biomarker assays, while superficially appealing from a regulatory perspective, fails to address the scientific requirements for reliable biomarker measurement.

Advancing the Scientific Discussion

Key questions for bioanalytical scientists to consider:

1. How does your team evaluate parallelism between calibrator material and endogenous analyte across different individual samples?
2. What approaches do you use to establish and verify analytical ranges when working with endogenous molecules?
3. How do you integrate ongoing in-study validation data to refine your understanding of method performance with actual biological samples?

Guidance Documents

For reference, you can find the relevant guidance documents here:

• January 2025 – Bioanalytical Method Validation for Biomarkers Guidance for Industry https://www.fda.gov/media/185276/download
• November 2022 – M10 BIOANALYTICAL METHOD VALIDATION AND STUDY SAMPLE ANALYSIS Guidance for Industry https://www.fda.gov/media/162903/download
• May 2018 – Bioanalytical Method Validation Guidance for Industry https://www.fda.gov/media/70858/download